Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Dihydroergotamine · Atzumi, Brekiya

Small molecule · Agonist of 5-HT1D receptor (HTR1D) · developed by Bausch

Approved FDA, Apr 1946
1 Registered trials

What is Dihydroergotamine?

Dihydroergotamine is an ergotamine derivative that binds with high affinity to 5-HT1D receptors and acts as an agonist at them. It is used in the acute treatment of migraine, and one label also covers acute cluster headache.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as
Atzumi, Brekiya, Dihydroergotamine Mesylate, Trudhesa, MAP-0004
Drug type
Small molecule
Targets
5-HT1D receptor (HTR1D)
Mechanism
Agonist of 5-HT1D receptor (HTR1D)
Therapy area
Neurology
Developer
Bausch
In trials of
PULM
FDA status
Approved as Atzumi, Brekiya, Dihydroergotamine Mesylate (April 12, 1946), NDA005929 · FDA label
UNII
436O5HM03C

✅ FDA-approved uses

From the indications section of the FDA label (version of Sep 3, 2026). Read the full label for the exact wording, limitations and safety information.

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT05351086 Phase 1 Healthy Completed PULM

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Healthy

Other drugs acting on HTR1D

Sources

Updated Oct 25, 2026.

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.